IBSA
Challenge, resilience, courage, nature, innovation. These are the keywords that characterise Sailing into the Future. Together , the new international project that sees IBSA (Institut Biochimique SA) the protagonist of a new three-year enterprise, which starts in 2022, albeit with a long-term vision.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220316005863/en/
“The project we are launching today is a real sporting endeavour, which sees us compete in some of the world’s most prestigious and challenging regattas”, stated Arturo Licenziati, President, CEO and Founder of IBSA . “This new project, however, is not only an ocean crossing, but also an opportunity to tell the values of IBSA, increasing its visibility around the world. In fact, IBSA is today an international company that maintains a vision that is always aimed at the future and ready to face challenges that go well beyond the therapeutic and personal care areas ”.
Founded in 1945 and headquartered in Lugano (Switzerland), IBSA is a leading scientific, economic and industrial reality in the pharmaceutical sector, thanks to the design outlined by Arturo Licenziati. A multinational company employing 2,000 people – including headquarters, subsidiaries and production sites – IBSA is present with its products in over 90 countries on 5 continents, with 16 subsidiaries located in Europe, China and the United States and with a turnover of over CHF 700 million.
“Innovating by keeping people at the core of our ecosystem, without ever setting limits: those are the horizons of the IBSA Group, which has always been inspired by the desire to go further ”, explained Licenziati . “ Sailing into the future. Together is a metaphor for our corporate history, but also a wish to grow and change, to find new means to offer health, well-being and new perspectives for the communities within which we operate, through social and environmental sustainability ”.
The project Sailing into the Future. Together engaged a team of great experience and sporting talent, involved right from the design and building phase of an innovative Class40 boat that will be led by Alberto Bona , the skipper who has been entrusted with the task of transforming this undertaking into a success.
“The Route du Rhum is the first stage of a three-year project: it’s one of the most challenging solo regattas in the world, as well as one of the most popular events in international ocean sailing. The project relies on a competent and greatly experienced team, while the conceptual design of the boat and its construction are entrusted to a successful duo: thus, we have all the credentials to put a winning boat in the water. The further challenge will be to make the most of the time available after the July launch, and carry out the in-water test part to make it reliable and performing ”, commented Alberto Bona . “Naturally, I thank our sponsor IBSA, with which I share the taste for the challenge, for continuous improvement, and the desire to break through new horizons. IBSA has chosen sailing to represent strength, determination, innovation, but also to raise awareness about a greater respect for nature, with a view to sustainability ”.
Beyond sport, and in a broader perspective, sailing is part of a path that brings the Company ever closer to the topic of sustainability , promoting respect for nature and the environment, but also to a new sensitivity and awareness about issues of collective responsibility , with activities in favour of people in difficulty or with disabilities.
“As part of this project, we decided to be a partner of some nautical clubs, in order to support inclusive sailing initiatives. We started a collaboration with the Yacht Club of Punta Ala (GR), to which we donated two boats for disabled children, to involve them in experiences in close contact with the sea, enabling them to navigate with accessible boats and compete in integrated races ”, explained Giorgio Pisani, Vice President Southern Europe and Project Leader . “The goal is to create an actual inclusion of the disabled on the competition field, promoting social integration as well as opportunities for dialogue, interaction and mutual understanding, thus helping break down barriers and differences ”.
The Company will also receive a prize during the award ceremony of the first edition (2022) of the Sport for Nature Awards – to be held today, March 17, 2022 – an event that aims to celebrate the “sport with a green soul”.
The award Azienda per il sociale: IBSA per la vela inclusiva (“Company for social initiatives: IBSA for inclusive sailing”) will be assigned precisely for raising awareness in favour of social and environmental sustainability through the values of sport, and in particular of sailing, as a means for social inclusion.
To narrate all the phases of the project Sailing into the Future. Together and accompany its development, the new website www.ibsasailing.com was created, also available in Italian and French . From here, it will be possible to follow the journey of skipper Alberto Bona, find out more about the Route du Rhum , the team and the new Class40 boat, that will set sail on November 6 from Saint-Malo, headed towards the island of Guadeloupe. In addition, the site will host photo and video content and news relating to IBSA’s social responsibility initiatives.
IBSA
IBSA (Institut Biochimique SA) is a multinational pharmaceutical Swiss Company, founded in 1945 in Lugano. Today, its products are present in over 90 Countries on 5 continents, through the Company’s 16 subsidiaries located in Europe, China and the United States. The company has a consolidated turnover of over 700 million Swiss francs, and employs 2,000 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents and others in development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardio-metabolic, respiratory, consumer health. It is also one of the four largest operators worldwide in the area of Reproductive Medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on 4 pillars: Person, Innovation, Quality and Responsibility.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005863/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel Launches RG660QA and RG660QB 5G Modules With Advanced Performance Features7.1.2026 18:00:00 CET | Press release
Quectel Wireless Solutions, an end-to-end global IoT solutions provider, today announces the launch of the RG600QA and RG660QB 5G module, based on the Qualcomm® X85 and X82 5G Modem-RF Systems. The RG660QA is based on X85 while the RG660QB is based onX82. Engineering samples of two first SKUs in the RG660Qx series have been already made available to customers and pre-production samples will be available to the market in Q2 2026. Designed for versatility, this module series supports a broad array of next generation 5G use cases, from home and business wireless broadband to mobile video, camera applications, and high-performance mobile hotspots. In indoor 5G CPE, it unlocks premium performance by enabling Wi-Fi 7 across the 2.4 GHz, 5 GHz, and 6 GHz bands, with integrated Bluetooth to support a full ecosystem of connected devices. With Ethernet speeds reaching up to 10 Gbps, the RG660Qx delivers the high-capacity backbone needed to power ultra-fast, reliable home and enterprise networks.
Sodali & Co Announces Executive Leadership Appointments7.1.2026 17:00:00 CET | Press release
Accelerates Firm Strategy to Deliver Global Integrated Stakeholder Solutions Sodali & Co (the ‘firm’ or ‘Sodali’), the leading global capital markets-centric stakeholder advisory firm, is pleased to announce four appointments to its Executive Leadership Team (ELT) under Chief Executive Officer Andrew Benett. These newly created senior roles will strengthen Sodali’s ability to respond to clients’ evolving needs with an integrated suite of shareholder, sustainability, and strategic communications advisory services delivered on a global scale. The appointments are as follows: Brett Clegg has been promoted to Chief Commercial Officer. Brett was previously Chairman of Sodali’s APAC region, based in the firm’s Sydney office. He specializes in advising clients on strategic communications, issues management, and capital markets transactions. Prior to Sodali, Brett spent over two decades in senior executive and editorial roles at some of Australia’s leading news brands, including The Australian
1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 14:15:00 CET | Press release
In 2025 1NCE added another 10 million endpoints to its foundational IoT platform; now manages 40+ million intelligent products for 30,000 customers in 17 industries. Introduces new software, 1NCE Insights, the AI + IoT fusion of intelligence from its network that gives analytics and benchmark data on how customers can better setup, manage and optimize their device estates. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 14:00:00 CET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
